Table 1.

Studies with high-dose SGLT2 and dual SGLT1 and SGLT2 inhibitors in people with T1D

	Clinical Trials in People with Type 1 Diabetes
	DEPICT 1	DEPICT 2	inTandem 1	inTandem 2	inTandem 3	EASE 1	EASE 2	EASE 3
Number of patients,an	556	442	530	521	1402	37	487	486
Study drug	DAPA	DAPA	SOTA	SOTA	SOTA	EMPA	EMPA	EMPA
Drug high dose (mg)	10	10	400	400	400	25	25	25
Study duration (weeks)	52	24	52	52	24	4	52	26
Baseline HbA1c (%)	8.5	8.4	7.5	7.8	8.2	8.2	8.1	8.2
Change in HbA1cb (%)	−0.36	−0.42	−0.31	−0.32	−0.46	−0.49	−0.45	−0.52
Change in insulin TDDb (%)	∼−10	−11.1	−12.6	−8.2	−9.7	−13	−12.9	−12.6
Change in body weightb (kg)	−3.6	−3.0	−4.3	−2.9	−3.0	−1.9	−3.6	−3.4
Change in time in rangeb,c (%)	+10.7		+10.4	+13.4	NA	+10.9	+12.5	+7.4
Ketoacidosis incidence rates,d,en	13 versus 3	3 versus 0	11 versus 1	9 versus 0	21 versus 4	0 versus 0	16 versus 6

High-dose treatment with SGLT1 or SGLT2 inhibitor: dapagliflozin 10 mg, EMPA 25 mg or sotagliflozin 400 mg.

^aIncluding placebo and high-dose SGLT1 or SGLT2 inhibitor treatment group.

^bPlacebo-adjusted.

^cCGM data for DEPICT-1 and DEPICT-2 were pooled for analyses.

^dIncidence rates for SGLT1/2 inhibitor versus placebo.

^eKetoacidosis incidence rates were pooled for EASE 2 and EASE 3 studies.

DAPA: dapagliflozin; SOTA, sotagliflozin; TDD, total daily dosage; NA, not available.